We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Metastatic Breast Cancer
Center of Excellence
Interested in receiving weekly updates about the Metastatic Breast Cancer Center of Excellence?
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Andrea de Matteis
May 17, 2017
Modified radical mastectomy
Oda Abushaban
May 18, 2017
For hormone therapy
Vijay Devanhalli
May 19, 2017
Surgery is ruled out at present. What are the toxicities of the regimen you have recommended ?
HAMDI Djelloul
May 26, 2017
neoadjuvant double-blocade-her2 (trastu + pertu) and aromatase inhibitor. I don't think that a PDK4-6 inhibitor is reasonable.If a complete clinical response is observed, surgery could be avoided ; RT can be performed.
Alisan ZIRTILOGLU
May 27, 2017
Only data about combining an anti-HER2 agent and hormonotherapy comes from a subset of a study with metastatic disease. In the study of Johnston S. et al, lapatinib in combination with letrozole increased PFS over letrozole alone.
But, regarding combining an anti-HER2 agent with hormonotherapy and a CDK 4/6 inhibitor, as far as I know, there is no data in literature.
Maybe AI only or combination with anti HER2 therapy could be the reasonable choice for treatment in this patient.
Najam Ul Hassan
Apr 25, 2018
For Surgery (MRM) followed by anti-HER2 plus A.I with supportive treatment for bone health.
Apr 20, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Sameer
Nasir
MD
Andrea de Matteis
May 17, 2017
Oda Abushaban
May 18, 2017
Vijay Devanhalli
May 19, 2017
HAMDI Djelloul
May 26, 2017
Alisan ZIRTILOGLU
May 27, 2017
Najam Ul Hassan
Apr 25, 2018
Apr 20, 2024
Pending Moderator approval.